Neuraminidase Inhibitors for Influenza A and B Treatment, 1999 CDC Report

A 1999 report from the Centers for Disease Control and Prevention (CDC) details the approval and use of neuraminidase inhibitors, zanamivir and oseltamivir, for treating influenza A and B infections. The report provides specific usage criteria, such as patient age and symptom duration, and contextualizes these drugs within the broader U.S. antiviral strategy. It references an average of approximately 20,000 influenza-related deaths per year in the United States.

Use Cases

• Analyzing the historical timeline of antiviral drug approvals based on the specific years mentioned in the description
• Studying treatment criteria for influenza antivirals based on patient age and symptom duration parameters described
• Comparing different classes of influenza antiviral drugs based on the mentions of amantadine, rimantadine, and neuraminidase inhibitors

Strengths

• Provides specific historical dates for drug approvals, such as 1999 for neuraminidase inhibitors
• Includes concrete public health statistics, citing an average of approximately 20,000 influenza-related deaths per year in the U.S.
• Details precise treatment criteria, including patient age thresholds and a 2-day symptom window

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• Last update date is unknown; freshness unverified

Provenance

Source

Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP)

Collection Method

Likely a published report or official recommendation document.

Time Range

Focuses on information current as of 1999, with historical context dating back to 1966.

Geography

United States